Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tulisokibart - Merck & Co

Next Previous
X
Search
Drug Profile

Tulisokibart - Merck & Co

Alternative Names: MK-7240; PRA-023

Latest Information Update: 20 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prometheus Biosciences
  • Developer Merck & Co; Prometheus Biosciences
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis
  • Phase II Systemic scleroderma
  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 25 Nov 2024 Merck Sharp & Dohme initiates a phase III trial for Crohn's disease (In adolescents, In adults, In the elderly, Treatment-experienced) in USA (SC) (NCT06651281)(EudraCT2024-513533-20)
  • 25 Nov 2024 Merck Sharp & Dohme initiates a phase III trial for Ulcerative Colitis (In adolescents, In adults, In the elderly, Treatment-experienced) in USA (SC) (NCT06651281)(EudraCT2024-513533-20)
  • 21 Oct 2024 Merck Sharp & Dohme plans a phase III trial for Crohn's disease and Ulcerative colitis (In adolescents, In adults, In the elderly, Treatment-experienced) (SC) in December 2024 (NCT06651281)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top